Prostate And Other Male Cancers

Hemodilution Lowers PSA Levels

Hemodilution from increased circulating plasma volumes could explain why obese men with prostate cancer have lower serum PSA levels than non-obese men with the malignancy, according to researchers.

Novel Agent May Benefit Men with Metastatic HRPC

CHICAGO—A new compound that specifically inhibits production of the cell-survival protein clusterin appears to be well tolerated and produces PSA responses when given in combination with docetaxel and prednisone in men with metastatic hormone refractory prostate cancer (HRPC), a study found.

PCa Death Decline Tied To Screening

ANAHEIM, Calif.—Declines in prostate cancer deaths are associated with an increase in PSA screening, although the effect is greater in white than in black men, according to researchers at the University of Alabama-Birmingham.

Testosterone Considered Safe for Older Men

TORONTO—Six months of testosterone supplementation in older men with moderately low testosterone levels appears to be relatively safe, with little or no negative effects on the prostate, according to researchers in The Netherlands.

PCPs May Miss LUTS Cases

ANAHEIM, Calif.—Moderate to severe lower urinary tract symptoms (LUTS) are present in 42% of men over age 50 who visit their primary-care physician (PCP), according to data presented here at the American Urological Association annual meeting.

Watchful Waiting Risks Quantified

ANAHEIM, Calif.—Fifteen percent of older men managed with watchful waiting for low-risk prostate tumors detected by PSA screening will die from the malignancy in 10 years, despite a high death rate from competing causes, a study found.

Statins Found to Decrease PSA Levels

ANAHEIM, Calif.—Statins can significantly reduce PSA levels in healthy men, and the magnitude of this decline is proportional to the extent to which the drugs reduce cholesterol levels, according to researchers.

Next post in News